Between 2024 and 2026, the number of Americans who personally know someone who has used a GLP-1 for weight loss has increased from 21% to 31% 1 , reflecting how quickly these therapies have entered the mainstream
While it may remain stable for slightly longer, its efficacy will steadily decline, so we recommend using it as quickly as possible for reliable research
Rest if Needed: Some patients feel deeply relaxed after treatment
Adoption remained modest until recent years as GLP-1 drug claims rose from 6.9 percent in 2023 to 10.5 percent in 2025
It helps both insured and uninsured individuals discover discounts on medications, including both brand name and generic drugs, at over 70,000 local pharmacies using coupons
J Neurosci 35(11):45824586 Cork SC et al (2015) Distribution and characterisation of glucagon-like peptide-1 receptor expressing cells in the mouse brain